Prescribing information




The first and only fully human IL-17A inhibitor:1


Image of the number 250,000 plus

Cosentyx patients treated since launch2*

Image of the words 'Recommended by BAD'

as a first-line biologic for patients with PsO, with or without PsA3

 Image of the words 'Real-world evidence'

from BADBIR, one of the largest psoriasis registers in the world4

See more


Helping your patients LOOK BETTER, MOVE BETTER, FEEL BETTER5–9

Look better, fast and sustained skin clearance  Move better, sustained efficacy in PsA Feel better, quality of life improvement rates were sustained up to 5 years

*Worldwide, across all licensed indications.2

n=167. CLEAR study: Efficacy data reported as non-responder imputation, in patients with moderate to severe psoriasis. Primary endpoint was met: Superiority of secukinumab to ustekinumab in achieving PASI 90 response at week 16 in overall patient population (P<0.0001).7

n=122. Patients with moderate to severe plaque psoriasis, who completed 52 weeks of the SCULPTURE study, could enter this extension study, which was double-blind until Year 3, and thereafter was unblinded to Year 5. Efficacy data were reported as observed; no P values were reported.5

**In PsA patients who have moderate to severe plaque psoriasis and/or are anti-TNF inadequate responders, the recommended dose of Cosentyx is 300 mg; in all other PsA patients the recommended initial dose is 150 mg – this may be increased to 300 mg based on clinical response.1

§n=53/74 and n=39/74 respectively. FUTURE 1: Primary endpoint was met: ACR 20 response at week 24, in overall patient population (P<0.001).12 Those patients who completed the 2-year core trial entered the 3-year extension study (N=236). Efficacy data were reported as observed.8

ACR, American College of Rheumatology criteria; AS, ankylosing spondylitis; BAD, British Association of Dermatologists; BADBIR, British Association of Dermatologists Biologic and Immunomodulators Register; DMARD, disease-modifying anti-rheumatic drug; IL, interleukin; MTX, methotrexate; PASI, psoriasis area severity index; PsA, psoriatic arthritis; PsO, plaque psoriasis; QoL, quality of life, TNF, tumour necrosis factor alpha.


  1. Cosentyx Summary of Product Characteristics.
  2. Rheumatology DOF UK 244.
  3. Smith CH et al. Br J Dermatol 2020; doi:10.1111/bjd.19039.
  4. Yiu et al. Br J Dermatol 2020; doi:10.1111/bjd.18981.
  5. Bissonnette R et al. J Eur Acad Dermatol Venereol 2018;32:1507–1514.
  6. Langley RG et al. N Engl J Med 2014;371(4):326–338.
  7. Thaci D et al. J Am Acad Dermatol 2015;7(3):400–409.
  8. Mease PJ et al. ACR Open Rheumatology 2020;2(1):18–25.
  9. Baraliakos X et al. RMD Open 2019;5(2):e001005.
  10. Rheumatology DOF UK 215.
  11. Rheumatology DOF UK 243.
  12. Mease PJ, et al. N Engl J Med. 2015 Oct;373:1329–39.
COS20-C008 May 2020.

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the patient safety information (PSI) tool at
If you have a question about the product, please contact Medical Information on 01276 692255 or by email at [email protected]